Literature DB >> 9405310

Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF.

M Prat1, T Crepaldi, S Pennacchietti, F Bussolino, P M Comoglio.   

Abstract

Hepatocyte growth factor, also known as scatter factor, is a pleiotropic cytokine, which stimulates cell motility, invasion, proliferation, survival and morphogenesis, and induces the expression of specific genes by activating its receptor tyrosine kinase. In this work we have isolated, characterized and used as agonists two monoclonal antibodies (mAbs) directed against the extracellular domain of HGF receptor to investigate the requirements for receptor activation and for the different biological responses. The two mAbs display similar affinities, react with epitopes different from the hepatocyte growth factor binding site, and behave as either full or partial agonists. The full agonist mAb (DO-24) triggers all the biological effects elicited by hepatocyte growth factor, namely motility, proliferation, cell survival, invasion, tubulogenesis and angiogenesis. The partial agonist mAb (DN-30) induces only motility. Only the full agonist mAb is able to induce and sustain the expression of urokinase-type plasminogen activator receptor for prolonged periods of time, while both mAbs up-regulate the constitutive expression of urokinase-type plasminogen activator. Both mAbs activate receptor phosphorylation, which, being strictly dependent on mAb bivalence, requires receptor dimerization. Since simple receptor dimerization is not sufficient to trigger full biological responses, we propose that the region on the ss chain of the receptor recognized by the full agonist mAb is crucial for optimal receptor activation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9405310     DOI: 10.1242/jcs.111.2.237

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  65 in total

Review 1.  Role of MetMAb (OA-5D5) in c-MET active lung malignancies.

Authors:  Mosmi Surati; Premal Patel; Amy Peterson; Ravi Salgia
Journal:  Expert Opin Biol Ther       Date:  2011-12       Impact factor: 4.388

Review 2.  MET targeted therapy for lung cancer: clinical development and future directions.

Authors:  Yan Feng; Patrick C Ma
Journal:  Lung Cancer (Auckl)       Date:  2012-08-09

3.  Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody.

Authors:  Simona Cignetto; Chiara Modica; Cristina Chiriaco; Lara Fontani; Paola Milla; Paolo Michieli; Paolo M Comoglio; Elisa Vigna
Journal:  Mol Oncol       Date:  2016-03-28       Impact factor: 6.603

4.  Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor.

Authors:  Elisa Vigna; Giovanni Pacchiana; Cristina Chiriaco; Simona Cignetto; Lara Fontani; Paolo Michieli; Paolo M Comoglio
Journal:  J Mol Med (Berl)       Date:  2013-09-07       Impact factor: 4.599

5.  MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM.

Authors:  Jessica B Casaletto; Melissa L Geddie; Adnan O Abu-Yousif; Kristina Masson; Aaron Fulgham; Antoine Boudot; Tim Maiwald; Jeffrey D Kearns; Neeraj Kohli; Stephen Su; Maja Razlog; Andreas Raue; Ashish Kalra; Maria Håkansson; Derek T Logan; Martin Welin; Shrikanta Chattopadhyay; Brian D Harms; Ulrik B Nielsen; Birgit Schoeberl; Alexey A Lugovskoy; Gavin MacBeath
Journal:  Proc Natl Acad Sci U S A       Date:  2019-03-21       Impact factor: 11.205

6.  Disassociation of met-mediated biological responses in vivo: the natural hepatocyte growth factor/scatter factor splice variant NK2 antagonizes growth but facilitates metastasis.

Authors:  T Otsuka; J Jakubczak; W Vieira; D P Bottaro; D Breckenridge; W J Larochelle; G Merlino
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

7.  Increase of MET gene copy number confers resistance to a monovalent MET antibody and establishes drug dependence.

Authors:  Valentina Martin; Simona Corso; Paolo M Comoglio; Silvia Giordano
Journal:  Mol Oncol       Date:  2014-06-24       Impact factor: 6.603

8.  Met receptor tyrosine kinase degradation is altered in response to the leucine-rich repeat of the Listeria invasion protein internalin B.

Authors:  Xiu Gao; Marta Lorinczi; Kristen S Hill; Natasha C Brooks; Hatem Dokainish; Keith Ireton; Lisa A Elferink
Journal:  J Biol Chem       Date:  2008-11-06       Impact factor: 5.157

Review 9.  Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy.

Authors:  Vikas Bhardwaj; Tina Cascone; Maria Angelica Cortez; Arya Amini; Jaden Evans; Ritsuko U Komaki; John V Heymach; James W Welsh
Journal:  Cancer       Date:  2013-02-19       Impact factor: 6.860

10.  Engineering a monomeric Fc domain modality by N-glycosylation for the half-life extension of biotherapeutics.

Authors:  Tetsuya Ishino; Mengmeng Wang; Lidia Mosyak; Amy Tam; Weili Duan; Kristine Svenson; Alison Joyce; Denise M O'Hara; Laura Lin; William S Somers; Ronald Kriz
Journal:  J Biol Chem       Date:  2013-04-24       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.